Global Tumor-specific Antigen Market
Report Scope:
The scope of this report is broad and covers category, source and applications of Tumor-specific Antigen. The market has been segmented by source into coding region and Non-Coding region. Revenue forecasts from 2017 to 2023 are given for each segment and regional market with estimated value derived from the revenue of manufacturers.
The report also includes a discussion of the major players across each region of the Tumor-specific antigen market. Further, it explains the major drivers and regional dynamics of the global Tumor-specific antigen market and current trends within the industry.
The report concludes with a special focus on vendor landscape and includes detailed profiles of the main vendors in the Tumor-specific antigen market.
Report Includes:
The scope of this report is broad and covers category, source and applications of Tumor-specific Antigen. The market has been segmented by source into coding region and Non-Coding region. Revenue forecasts from 2017 to 2023 are given for each segment and regional market with estimated value derived from the revenue of manufacturers.
The report also includes a discussion of the major players across each region of the Tumor-specific antigen market. Further, it explains the major drivers and regional dynamics of the global Tumor-specific antigen market and current trends within the industry.
The report concludes with a special focus on vendor landscape and includes detailed profiles of the main vendors in the Tumor-specific antigen market.
Report Includes:
- 75 data tables and 61 additional tables
- An overview of the global market for tumor-specific antigen
- Analyses of global market trends, with data from 2017, 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Coverage of various types of product available in the tumor-specific antigen market and discussion of their potential applications
- Information on oncofetal, oncoviral, overexpressed/accumulated, mutated, lineage restricted and idiotypic tumor-specific antigens and discussion of their specific targets
- Insights into regulatory framework and policies and funding initiatives by the government for cancer research
- A look into advancements in antigen specific T-Cell therapy for cancer and innovation within the industry
- Detailed profiles of the major vendors in the global tumor-specific antigen market including Agilent Technologies Inc., AIVITA Biomedical, Eli Lilly and Co., GO Therapeutics and Merck Millipore
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst’s Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
Market Overview
Market Potential
Investment Analysis
Regulatory Framework
United States
European Union
Australia
Japan
India
China
Industry Growth Drivers
Surging Demand for Potential Cancer Biomarker Candidates
Rising Prevalence of Cancer
Increasing Investments in Cancer Diagnosis and Research
Rising Focus on Developing Targeted Therapies
Antigen Specific T-Cell Therapy
CHAPTER 4 TUMOR-SPECIFIC ANTIGEN MARKET BY CATEGORY
Oncofetal
Oncoviral
Overexpressed/Accumulated
CT9/CT10
Mutated
Lineage-Restricted Antigen
Idiotypic
Others
CHAPTER 5 TUMOR-SPECIFIC ANTIGEN MARKET BY SOURCE
Coding Region
Non-Coding Region
Growing the Background of Immunotherapy Targets
CHAPTER 6 TUMOR-SPECIFIC ANTIGEN MARKET BY APPLICATION
Diagnostics
Drug Discovery and Development
Therapeutics
Risk Assessment
Prognostics
Clinical and Basic Research
CHAPTER 7 TUMOR-SPECIFIC ANTIGEN MARKET BY REGION
North America
United States
Canada
Europe
United Kingdom
France
Germany
Spain
Rest of Europe
Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
Rest of the World
Latin America
Middle East and Africa
CHAPTER 8 TUMOR-SPECIFIC ANTIGEN MARKET INDUSTRY STRUCTURE
Industry Structure
Procurement of Raw Materials
Manufacturing/Development Process
End-Users
Innovation in the Market
Competitive Analysis
CHAPTER 9 COMPANY PROFILES
ABCAM PLC
AGILENT TECHNOLOGIES INC.
AIVITA BIOMEDICAL
BBI GROUP
BIOMЙRIEUX SA
BIO-RAD LABORATORIES INC.
BRIGHTPATH BIOTHERAPEUTICS
CARIS LIFE SCIENCES INC.
CISBIO BIOASSAYS
CREATIVE DIAGNOSTICS
ELI LILLY AND CO.
ENZO BIOCHEM INC.
EXTERNAUTICS
F. HOFFMANN-LA ROCHE LTD.
GO THERAPEUTICS
JANSSEN GLOBAL SERVICES LLC
LEE BIOSOLUTIONS INC.
MERCK MILLIPORE
MESO SCALE DIAGNOSTICS, LLC
PERKINELMER INC.
QUEST DIAGNOSTICS
SIGNOSIS INC.
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst’s Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
Market Overview
Market Potential
Investment Analysis
Regulatory Framework
United States
European Union
Australia
Japan
India
China
Industry Growth Drivers
Surging Demand for Potential Cancer Biomarker Candidates
Rising Prevalence of Cancer
Increasing Investments in Cancer Diagnosis and Research
Rising Focus on Developing Targeted Therapies
Antigen Specific T-Cell Therapy
CHAPTER 4 TUMOR-SPECIFIC ANTIGEN MARKET BY CATEGORY
Oncofetal
Oncoviral
Overexpressed/Accumulated
CT9/CT10
Mutated
Lineage-Restricted Antigen
Idiotypic
Others
CHAPTER 5 TUMOR-SPECIFIC ANTIGEN MARKET BY SOURCE
Coding Region
Non-Coding Region
Growing the Background of Immunotherapy Targets
CHAPTER 6 TUMOR-SPECIFIC ANTIGEN MARKET BY APPLICATION
Diagnostics
Drug Discovery and Development
Therapeutics
Risk Assessment
Prognostics
Clinical and Basic Research
CHAPTER 7 TUMOR-SPECIFIC ANTIGEN MARKET BY REGION
North America
United States
Canada
Europe
United Kingdom
France
Germany
Spain
Rest of Europe
Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
Rest of the World
Latin America
Middle East and Africa
CHAPTER 8 TUMOR-SPECIFIC ANTIGEN MARKET INDUSTRY STRUCTURE
Industry Structure
Procurement of Raw Materials
Manufacturing/Development Process
End-Users
Innovation in the Market
Competitive Analysis
CHAPTER 9 COMPANY PROFILES
ABCAM PLC
AGILENT TECHNOLOGIES INC.
AIVITA BIOMEDICAL
BBI GROUP
BIOMЙRIEUX SA
BIO-RAD LABORATORIES INC.
BRIGHTPATH BIOTHERAPEUTICS
CARIS LIFE SCIENCES INC.
CISBIO BIOASSAYS
CREATIVE DIAGNOSTICS
ELI LILLY AND CO.
ENZO BIOCHEM INC.
EXTERNAUTICS
F. HOFFMANN-LA ROCHE LTD.
GO THERAPEUTICS
JANSSEN GLOBAL SERVICES LLC
LEE BIOSOLUTIONS INC.
MERCK MILLIPORE
MESO SCALE DIAGNOSTICS, LLC
PERKINELMER INC.
QUEST DIAGNOSTICS
SIGNOSIS INC.
LIST OF TABLES
Summary Table: Global Market for Tumor-specific Antigen, by Source, Through 2023
Table 1: Investment Analysis
Table 2: Biomarkers for Cancer Detection, Diagnosis and Prognosis
Table 3: Protein Arrays: Cancer Biomarker Discovery
Table 4: Global Prevalence of Cancer, by Type, 2016
Table 5: Regional Cancer Prevalence, by Type, 2015 and 2016
Table 6: Investment in Cancer, by Area of Research, 2017
Table 7: Investments in Cancer-Based Research, 2016-2018
Table 8: Molecular Targeted Therapy in Anticancer
Table 9: CAR Target Antigen for Hematologic Malignancies and Potential Off-Tumor Targets
Table 10: Global Market for Tumor-specific Antigen, by Category, Through 2023
Table 11: Tumor Antigen
Table 12: Global Market for Oncofetal Antigen, by Region, Through 2023
Table 13: Pharmaceutical and Bioinformatic Partnerships and Alliances
Table 14: Global Market for Oncoviral Antigen, by Region, Through 2023
Table 15: U.S. R&D Funding for Basic Research
Table 16: Global Market for Overexpressed/Accumulated Antigen, by Region, Through 2023
Table 17: Investment in Cancer, by Research Area
Table 18: Global Market for CT9/CT10 Antigen, by Region, Through 2023
Table 19: Regional Cancer Prevalence, by Type, 2015 and 2016
Table 20: Global Market for Mutated Antigen, by Region, Through 2023
Table 21: Global Leukemia Deaths, 2016
Table 22: Estimated New Cases of Leukemia, Lymphoma and Myeloma in the U.S., 2018
Table 23: Global Market for Lineage Restricted Antigen, by Region, Through 2023
Table 24: Global Cancer Prevalence and Mortality Rate, 2012 and 2030
Table 25: Global Prevalence of Cancer, by Type, 2016
Table 26: Global Cancer Mortalities, by Type, 2016
Table 27: Global Market for Idiotypic-Based Antigen, by Region, Through 2023
Table 28: Clinical Trials in Idiotypic
Table 29: Identified Post-Translationally Modified AutoAntigen
Table 30: Global Market for Other Antigen, by Region, Through 2023
Table 31: Global Prevalence of Diabetes, 2017 and 2045
Table 32: Global Market for Tumor-specific Antigen, by Source, Through 2023
Table 33: Tumor and Tissue-Specific Promoters Used to Generate Tumor-specific Antigen Sourced Through Coding Region
Table 34: Global Market for Coding Region-Based Antigen, by Region, Through 2023
Table 35: Global Market for Non-Coding Region-Based Antigen, by Region, Through 2023
Table 36: Global Market for Tumor-specific Antigen, by Application, Through 2023
Table 37: Key Immunological Techniques for Diagnosis of Cancer
Table 38: Global Market for Tumor-specific Antigen in Diagnostic Applications, by Region, Through 2023
Table 39: Circulating Antigen and Immunodiagnosis of Cancer
Table 40: Global Market for Tumor-specific Antigen in Drug Discovery and Development Applications, by Region, Through 2023
Table 41: Clinical Trials Involving Tumor-specific Antigen for Cancer Therapeutics
Table 42: Global Market for Tumor-specific Antigen in Therapeutic Applications, by Region, Through 2023
Table 43: Global Market for Tumor-specific Antigen in Risk Assessment Applications, by Region, Through 2023
Table 44: Global Market for Tumor-specific Antigen in Prognostic Applications, by Region, Through 2023
Table 45: Global Prevalence of Different Cancers, by Country, 2016
Table 46: Deaths from Different Cancer Type, by Country, 2016
Table 47: NCI Funding, 2012-2017
Table 48: Global Market for Tumor-specific Antigen in Clinical and Basic Research Applications, by Region, Through 2023
Table 49: North American Market for Tumor-specific Antigen, by Country, Through 2023
Table 50: North American Market for Tumor-specific Antigen, by Category, Through 2023
Table 51: U.S. Funding for Cancer Research, by Type, 2015 and 2016
Table 52: North American Market for Tumor-specific Antigen, by Source, Through 2023
Table 53: U.S. Market for Tumor-specific Antigen, by Source, Through 2023
Table 54: Canadian Market for Tumor-specific Antigen, by Source, Through 2023
Table 55: North American Market for Tumor-specific Antigen, by Application, Through 2023
Table 56: European Market for Tumor-specific Antigen, by Country/Region, Through 2023
Table 57: European Market for Tumor-specific Antigen, by Category, Through 2023
Table 58: Cancer Prevalence in the U.K., by Country, 2015 and 2020
Table 59: European Market for Tumor-specific Antigen, by Source, Through 2023
Table 60: U.K. Market for Tumor-specific Antigen, by Source, Through 2023
Table 61: Funding for Biology and Basic Sciences for Cancer Research in France, 2007-2015
Table 62: French Market for Tumor-specific Antigen, by Source, Through 2023
Table 63: German Market for Tumor-specific Antigen, by Source, Through 2023
Table 64: Ongoing Cancer-Based Trials in Germany
Table 65: Cancer Cases in Spain, 2012 and 2015
Table 66: European Market for Tumor-specific Antigen, by Application, Through 2023
Table 67: Spanish Market for Tumor-specific Antigen, by Source, Through 2023
Table 68: Projects Recommended to the NCU Board for Funding, 2016
Table 69: Rest of European Market for Tumor-specific Antigen, by Source, Through 2023
Table 70: Asia-Pacific Market for Tumor-specific Antigen, by Country/Region, Through 2023
Table 71: Asia-Pacific Market for Tumor-specific Antigen, by Source, Through 2023
Table 72: Cancer Incidence in China, 2016
Table 73: Asia-Pacific Market for Tumor-specific Antigen, by Category, Through 2023
Table 74: Chinese Market for Tumor-specific Antigen, by Source, Through 2023
Table 75: Clinical Trials for Cancer
Table 76: Indian Market for Tumor-specific Antigen, by Source, Through 2023
Table 77: Asia-Pacific Market for Tumor-specific Antigen, by Application, Through 2023
Table 78: Japanese Market for Tumor-specific Antigen, by Source, Through 2023
Table 79: Australian Market for Tumor-specific Antigen, by Source, Through 2023
Table 80: Change in Cancer Prevalence in Other APAC Countries, 2005-2016
Table 81: Rest of APAC Market for Tumor-specific Antigen, by Source, Through 2023
Table 82: Clinical Trials for Tumor-specific Antigen: Singapore
Table 83: RoW Market for Tumor-specific Antigen, by Region, Through 2023
Table 84: Cancer Incidence in Brazil, 2016
Table 85: Latin American Market for Tumor-specific Antigen, by Source, Through 2023
Table 86: RoW Market for Tumor-specific Antigen, by Category, Through 2023
Table 87: Causes of Death in Argentina and Percentage Change, 2005-2016
Table 88: RoW Market for Tumor-specific Antigen, by Source, Through 2023
Table 89: RoW Market for Tumor-specific Antigen, by Application, Through 2023
Table 90: Cancer Prevalence in Kenya, by Type, 2015 and 2016
Table 91: Middle Eastern and African Market for Tumor-specific Antigen, by Source, Through 2023
Table 92: Global Suppliers of Tumor-specific Antigen Market
Table 93: Selected Tumor-specific Antigen Companies
Table 94: Cancer Antigen for Clinical Trials, as of January 2019
Table 95: Product Launches, Product Development and FDA Clearance
Table 96: Notable Mergers and Acquisitions
Table 97: Notable Agreements, Collaborations and Partnerships
Table 98: Notable Funding, Expansion and Divestment
Table 99: Abcam PLC: Product Portfolio
Table 100: Abcam PLC: Recent Developments
Table 101: Agilent Technologies Inc.: Product Portfolio
Table 102: Agilent Technologies Inc.: Recent Developments
Table 103: AIVITA Biomedical: Product Portfolio
Table 104: AIVITA Biomedical: Recent Developments
Table 105: BBI Group: Product Portfolio
Table 106: Biomйrieux SA: Product Portfolio
Table 107: Bio-Rad Laboratories Inc.: Product Portfolio
Table 108: Bio-Rad Laboratories Inc.: Recent Developments
Table 109: BrightPath Biotherapeutics: Product Portfolio
Table 110: BrightPath Biotherapeutics: Recent Developments
Table 111: Caris Life Sciences Inc.: Product Portfolio
Table 112: Caris Life Sciences Inc.: Recent Developments
Table 113: Cisbio Bioassays: Product Portfolio
Table 114: Creative Diagnostics: Product Portfolio
Table 115: Creative Diagnostics: Recent Developments
Table 116: Eli Lilly and Co.: Product Portfolio
Table 117: Eli Lilly and Co.: Recent Developments
Table 118: Enzo Biochem Inc.: Product Portfolio
Table 119: Enzo Biochem Inc.: Recent Developments
Table 120: Externautics: Product Portfolio
Table 121: F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 122: F. Hoffmann-La Roche Ltd.: Recent Developments
Table 123: GO Therapeutics: Product Portfolio
Table 124: GO Therapeutics: Recent Developments
Table 125: Janssen Global Services LLC: Product Portfolio
Table 126: Janssen Global Services LLC: Recent Developments
Table 127: Lee Biosolutions Inc.: Product Portfolio
Table 128: Merck Millipore: Product Portfolio
Table 129: Merck Millipore: Recent Developments
Table 130: Meso Scale Diagnostics, LLC: Product Portfolio
Table 131: Meso Scale Diagnostics, LLC: Recent Developments
Table 132: PerkinElmer Inc.: Product Portfolio
Table 133: PerkinElmer Inc.: Recent Developments
Table 134: Quest Diagnostics: Product Portfolio
Table 135: Quest Diagnostics: Recent Developments
Table 136: Signosis Inc.: Product Portfolio
Summary Table: Global Market for Tumor-specific Antigen, by Source, Through 2023
Table 1: Investment Analysis
Table 2: Biomarkers for Cancer Detection, Diagnosis and Prognosis
Table 3: Protein Arrays: Cancer Biomarker Discovery
Table 4: Global Prevalence of Cancer, by Type, 2016
Table 5: Regional Cancer Prevalence, by Type, 2015 and 2016
Table 6: Investment in Cancer, by Area of Research, 2017
Table 7: Investments in Cancer-Based Research, 2016-2018
Table 8: Molecular Targeted Therapy in Anticancer
Table 9: CAR Target Antigen for Hematologic Malignancies and Potential Off-Tumor Targets
Table 10: Global Market for Tumor-specific Antigen, by Category, Through 2023
Table 11: Tumor Antigen
Table 12: Global Market for Oncofetal Antigen, by Region, Through 2023
Table 13: Pharmaceutical and Bioinformatic Partnerships and Alliances
Table 14: Global Market for Oncoviral Antigen, by Region, Through 2023
Table 15: U.S. R&D Funding for Basic Research
Table 16: Global Market for Overexpressed/Accumulated Antigen, by Region, Through 2023
Table 17: Investment in Cancer, by Research Area
Table 18: Global Market for CT9/CT10 Antigen, by Region, Through 2023
Table 19: Regional Cancer Prevalence, by Type, 2015 and 2016
Table 20: Global Market for Mutated Antigen, by Region, Through 2023
Table 21: Global Leukemia Deaths, 2016
Table 22: Estimated New Cases of Leukemia, Lymphoma and Myeloma in the U.S., 2018
Table 23: Global Market for Lineage Restricted Antigen, by Region, Through 2023
Table 24: Global Cancer Prevalence and Mortality Rate, 2012 and 2030
Table 25: Global Prevalence of Cancer, by Type, 2016
Table 26: Global Cancer Mortalities, by Type, 2016
Table 27: Global Market for Idiotypic-Based Antigen, by Region, Through 2023
Table 28: Clinical Trials in Idiotypic
Table 29: Identified Post-Translationally Modified AutoAntigen
Table 30: Global Market for Other Antigen, by Region, Through 2023
Table 31: Global Prevalence of Diabetes, 2017 and 2045
Table 32: Global Market for Tumor-specific Antigen, by Source, Through 2023
Table 33: Tumor and Tissue-Specific Promoters Used to Generate Tumor-specific Antigen Sourced Through Coding Region
Table 34: Global Market for Coding Region-Based Antigen, by Region, Through 2023
Table 35: Global Market for Non-Coding Region-Based Antigen, by Region, Through 2023
Table 36: Global Market for Tumor-specific Antigen, by Application, Through 2023
Table 37: Key Immunological Techniques for Diagnosis of Cancer
Table 38: Global Market for Tumor-specific Antigen in Diagnostic Applications, by Region, Through 2023
Table 39: Circulating Antigen and Immunodiagnosis of Cancer
Table 40: Global Market for Tumor-specific Antigen in Drug Discovery and Development Applications, by Region, Through 2023
Table 41: Clinical Trials Involving Tumor-specific Antigen for Cancer Therapeutics
Table 42: Global Market for Tumor-specific Antigen in Therapeutic Applications, by Region, Through 2023
Table 43: Global Market for Tumor-specific Antigen in Risk Assessment Applications, by Region, Through 2023
Table 44: Global Market for Tumor-specific Antigen in Prognostic Applications, by Region, Through 2023
Table 45: Global Prevalence of Different Cancers, by Country, 2016
Table 46: Deaths from Different Cancer Type, by Country, 2016
Table 47: NCI Funding, 2012-2017
Table 48: Global Market for Tumor-specific Antigen in Clinical and Basic Research Applications, by Region, Through 2023
Table 49: North American Market for Tumor-specific Antigen, by Country, Through 2023
Table 50: North American Market for Tumor-specific Antigen, by Category, Through 2023
Table 51: U.S. Funding for Cancer Research, by Type, 2015 and 2016
Table 52: North American Market for Tumor-specific Antigen, by Source, Through 2023
Table 53: U.S. Market for Tumor-specific Antigen, by Source, Through 2023
Table 54: Canadian Market for Tumor-specific Antigen, by Source, Through 2023
Table 55: North American Market for Tumor-specific Antigen, by Application, Through 2023
Table 56: European Market for Tumor-specific Antigen, by Country/Region, Through 2023
Table 57: European Market for Tumor-specific Antigen, by Category, Through 2023
Table 58: Cancer Prevalence in the U.K., by Country, 2015 and 2020
Table 59: European Market for Tumor-specific Antigen, by Source, Through 2023
Table 60: U.K. Market for Tumor-specific Antigen, by Source, Through 2023
Table 61: Funding for Biology and Basic Sciences for Cancer Research in France, 2007-2015
Table 62: French Market for Tumor-specific Antigen, by Source, Through 2023
Table 63: German Market for Tumor-specific Antigen, by Source, Through 2023
Table 64: Ongoing Cancer-Based Trials in Germany
Table 65: Cancer Cases in Spain, 2012 and 2015
Table 66: European Market for Tumor-specific Antigen, by Application, Through 2023
Table 67: Spanish Market for Tumor-specific Antigen, by Source, Through 2023
Table 68: Projects Recommended to the NCU Board for Funding, 2016
Table 69: Rest of European Market for Tumor-specific Antigen, by Source, Through 2023
Table 70: Asia-Pacific Market for Tumor-specific Antigen, by Country/Region, Through 2023
Table 71: Asia-Pacific Market for Tumor-specific Antigen, by Source, Through 2023
Table 72: Cancer Incidence in China, 2016
Table 73: Asia-Pacific Market for Tumor-specific Antigen, by Category, Through 2023
Table 74: Chinese Market for Tumor-specific Antigen, by Source, Through 2023
Table 75: Clinical Trials for Cancer
Table 76: Indian Market for Tumor-specific Antigen, by Source, Through 2023
Table 77: Asia-Pacific Market for Tumor-specific Antigen, by Application, Through 2023
Table 78: Japanese Market for Tumor-specific Antigen, by Source, Through 2023
Table 79: Australian Market for Tumor-specific Antigen, by Source, Through 2023
Table 80: Change in Cancer Prevalence in Other APAC Countries, 2005-2016
Table 81: Rest of APAC Market for Tumor-specific Antigen, by Source, Through 2023
Table 82: Clinical Trials for Tumor-specific Antigen: Singapore
Table 83: RoW Market for Tumor-specific Antigen, by Region, Through 2023
Table 84: Cancer Incidence in Brazil, 2016
Table 85: Latin American Market for Tumor-specific Antigen, by Source, Through 2023
Table 86: RoW Market for Tumor-specific Antigen, by Category, Through 2023
Table 87: Causes of Death in Argentina and Percentage Change, 2005-2016
Table 88: RoW Market for Tumor-specific Antigen, by Source, Through 2023
Table 89: RoW Market for Tumor-specific Antigen, by Application, Through 2023
Table 90: Cancer Prevalence in Kenya, by Type, 2015 and 2016
Table 91: Middle Eastern and African Market for Tumor-specific Antigen, by Source, Through 2023
Table 92: Global Suppliers of Tumor-specific Antigen Market
Table 93: Selected Tumor-specific Antigen Companies
Table 94: Cancer Antigen for Clinical Trials, as of January 2019
Table 95: Product Launches, Product Development and FDA Clearance
Table 96: Notable Mergers and Acquisitions
Table 97: Notable Agreements, Collaborations and Partnerships
Table 98: Notable Funding, Expansion and Divestment
Table 99: Abcam PLC: Product Portfolio
Table 100: Abcam PLC: Recent Developments
Table 101: Agilent Technologies Inc.: Product Portfolio
Table 102: Agilent Technologies Inc.: Recent Developments
Table 103: AIVITA Biomedical: Product Portfolio
Table 104: AIVITA Biomedical: Recent Developments
Table 105: BBI Group: Product Portfolio
Table 106: Biomйrieux SA: Product Portfolio
Table 107: Bio-Rad Laboratories Inc.: Product Portfolio
Table 108: Bio-Rad Laboratories Inc.: Recent Developments
Table 109: BrightPath Biotherapeutics: Product Portfolio
Table 110: BrightPath Biotherapeutics: Recent Developments
Table 111: Caris Life Sciences Inc.: Product Portfolio
Table 112: Caris Life Sciences Inc.: Recent Developments
Table 113: Cisbio Bioassays: Product Portfolio
Table 114: Creative Diagnostics: Product Portfolio
Table 115: Creative Diagnostics: Recent Developments
Table 116: Eli Lilly and Co.: Product Portfolio
Table 117: Eli Lilly and Co.: Recent Developments
Table 118: Enzo Biochem Inc.: Product Portfolio
Table 119: Enzo Biochem Inc.: Recent Developments
Table 120: Externautics: Product Portfolio
Table 121: F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 122: F. Hoffmann-La Roche Ltd.: Recent Developments
Table 123: GO Therapeutics: Product Portfolio
Table 124: GO Therapeutics: Recent Developments
Table 125: Janssen Global Services LLC: Product Portfolio
Table 126: Janssen Global Services LLC: Recent Developments
Table 127: Lee Biosolutions Inc.: Product Portfolio
Table 128: Merck Millipore: Product Portfolio
Table 129: Merck Millipore: Recent Developments
Table 130: Meso Scale Diagnostics, LLC: Product Portfolio
Table 131: Meso Scale Diagnostics, LLC: Recent Developments
Table 132: PerkinElmer Inc.: Product Portfolio
Table 133: PerkinElmer Inc.: Recent Developments
Table 134: Quest Diagnostics: Product Portfolio
Table 135: Quest Diagnostics: Recent Developments
Table 136: Signosis Inc.: Product Portfolio
LIST OF FIGURES
Summary Figure: Global Market for Tumor-specific Antigen, by Source, 2017-2023
Figure 1: Regional Prevalence of Cancer, 2015-2016
Figure 2: Global Prevalence of Cancer, by Type, 2016
Figure 3: Targeting of Tumor-specific Mutated Antigen in T-Cell Immunotherapy
Figure 4: Global Leukemia Deaths, 2016
Figure 5: Estimated New Cases of Leukemia, Lymphoma and Myeloma in the U.S., 2018
Figure 6: Global Cancer Prevalence and Mortality Rate, 2012 and 2030
Figure 7: Global Prevalence of Cancer, by Type, 2016
Figure 8: Global Cancer Mortalities, by Type, 2016
Figure 9: Determination of Antibody Idiotype
Figure 10: Global Prevalence of Diabetes, 2017 and 2045
Figure 11: Sources of Tumor-specific Antigen
Figure 12: Key Applications: Tumor-specific Antigen
Figure 13: Drug Discovery Cycle
Figure 14: Clinical Cancer Research for Therapeutic Applications
Figure 15: The Role of Prognostic and Predictive Markers in Individualized Treatment
Figure 16: Global Prevalence of Different Cancers, by Country, 2016
Figure 17: Deaths from Different Cancer Type, by Country, 2016
Figure 18: NCI Funding, 2012-2017
Figure 19: Funding for Biology and Basic Sciences for Cancer Research in France, 2007-2015
Figure 20: Cancer Incidence in China, 2016
Figure 21: Major Breakthroughs in Cancer Research: India
Figure 22: Cancer Prevalence in Kenya, by Type, 2015 and 2016
Figure 23: Tumor-specific Antigen Industry Structure
Figure 24: Tumor-specific Antigen Development Flow Chart
Summary Figure: Global Market for Tumor-specific Antigen, by Source, 2017-2023
Figure 1: Regional Prevalence of Cancer, 2015-2016
Figure 2: Global Prevalence of Cancer, by Type, 2016
Figure 3: Targeting of Tumor-specific Mutated Antigen in T-Cell Immunotherapy
Figure 4: Global Leukemia Deaths, 2016
Figure 5: Estimated New Cases of Leukemia, Lymphoma and Myeloma in the U.S., 2018
Figure 6: Global Cancer Prevalence and Mortality Rate, 2012 and 2030
Figure 7: Global Prevalence of Cancer, by Type, 2016
Figure 8: Global Cancer Mortalities, by Type, 2016
Figure 9: Determination of Antibody Idiotype
Figure 10: Global Prevalence of Diabetes, 2017 and 2045
Figure 11: Sources of Tumor-specific Antigen
Figure 12: Key Applications: Tumor-specific Antigen
Figure 13: Drug Discovery Cycle
Figure 14: Clinical Cancer Research for Therapeutic Applications
Figure 15: The Role of Prognostic and Predictive Markers in Individualized Treatment
Figure 16: Global Prevalence of Different Cancers, by Country, 2016
Figure 17: Deaths from Different Cancer Type, by Country, 2016
Figure 18: NCI Funding, 2012-2017
Figure 19: Funding for Biology and Basic Sciences for Cancer Research in France, 2007-2015
Figure 20: Cancer Incidence in China, 2016
Figure 21: Major Breakthroughs in Cancer Research: India
Figure 22: Cancer Prevalence in Kenya, by Type, 2015 and 2016
Figure 23: Tumor-specific Antigen Industry Structure
Figure 24: Tumor-specific Antigen Development Flow Chart
